Drug Profile
Research programme: multiple sclerosis therapeutics - Celtaxsys/Xeris
Alternative Names: CTX-4398; XeriJect™ Drug for MS; XeriSol™ Drug for MSLatest Information Update: 15 Oct 2021
Price :
$50
*
At a glance
- Originator Celtaxsys; XERIS Pharmaceuticals
- Developer Celtaxsys; Xeris Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Multiple sclerosis
Most Recent Events
- 05 Oct 2021 Strongbridge Biopharma and Xeris Pharmaceuticals has been acquired by Xeris Biopharma Holdings
- 16 Jul 2016 No recent reports of development identified for preclinical development in Multiple-sclerosis in USA (SC, Liquid)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Multiple-sclerosis in USA (SC, Paste)